Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData
GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.